TESPEBA
TESPEBA has been active since 2011 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €113k and a net result of €9k. Equity is growing by ~7.8% per year across the filed fiscal years. Its solvency ranks better than 77% of 501 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
| Equity | €113k |
| Net result | €9k |
| Better than sector | 77% |
| Active | 15 yrs |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 86.5% | 61.4% | |
| Net result | €9k | €29k | |
| Equity | €113k | €119k | |
| Gross operating margin | €13k | €67k | |
| Total assets | €131k | €282k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - | - |
| EBITDA | €13k | €11k | €6k | €11k | €8k |
| Net profit | €9k | €8k | €3k | €10k | €8k |
| Cash flow | €10k | €9k | €4k | €10k | €8k |
| Staff costs | - | - | - | - | - |
| Income taxes | €4k | €3k | €1k | €730 | - |
| Dividends | - | - | - | - | - |
| Total assets | €131k | €120k | €111k | €109k | €98k |
| Equity | €113k | €104k | €96k | €93k | €83k |
| Debt | €18k | €16k | €15k | €16k | €15k |
| of which ≤ 1y | €18k | €16k | €15k | €16k | €15k |
| of which > 1y | - | - | - | - | - |
| Working capital | €112k | €102k | €95k | €91k | €82k |
| Employees (FTE) | - | - | - | - | - |
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 7.32 | 7.17 | 7.26 | 6.82 | 6.65 |
| Quick ratio | 7.32 | 7.17 | 7.25 | 6.82 | 6.65 |
| Working capital ratio | 85.5% | 84.4% | 85.1% | 84.0% | 83.8% |
| Solvency | 86.5% | 86.3% | 86.4% | 85.6% | 85.2% |
| Debt / equity | 0.16 | 0.16 | 0.16 | 0.17 | 0.17 |
| Long-term debt ratio | - | - | - | - | - |
| Interest coverage | 113.16 | 82.40 | 62.43 | 83.12 | 115.15 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | 7.1% | 6.3% | 2.9% | 9.0% | 8.3% |
| ROE | 8.2% | 7.3% | 3.3% | 10.5% | 9.8% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Full annual accounts (23 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €131k | €120k | €111k | €109k | €98k |
| Fixed assets | 21/28 | €1k | €2k | €2k | €2k | €1k |
| Tangible fixed assets | 22/27 | €1k | €2k | €2k | €2k | €1k |
| Current assets | 29/58 | €130k | €118k | €110k | €107k | €96k |
| Stocks & contracts in progress | 3 | €87 | €54 | €104 | €105 | €105 |
| Amounts receivable within one year | 40/41 | €21k | €22k | €22k | €22k | €19k |
| Cash & bank | 54/58 | €108k | €96k | €87k | €85k | €78k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €131k | €120k | €111k | €109k | €98k |
| Equity | 10/15 | €113k | €104k | €96k | €93k | €83k |
| Contributions / capital | 10/11 | €6k | €6k | €6k | €6k | €6k |
| Reserves | 13 | €2k | €2k | €2k | €2k | €2k |
| Accumulated profits (losses) | 14 | €105k | €96k | €88k | €85k | €75k |
| Amounts payable | 17/49 | €18k | €16k | €15k | €16k | €15k |
| Amounts payable within one year | 42/48 | €18k | €16k | €15k | €16k | €15k |
| Trade debts payable within one year | 44 | €212 | - | €0 | €787 | €108 |
| Income statement | ||||||
| Gross operating margin | 9900 | €13k | €11k | €6k | €11k | €8k |
| Operating result | 9901 | €12k | €10k | €5k | €11k | €8k |
| Financial income | 75 | €1k | €421 | - | €5 | €3 |
| Financial charges | 65 | €116 | €135 | €90 | €134 | €72 |
| Result before taxes | 9903 | €13k | €10k | €4k | €10k | €8k |
| Income taxes | 67/77 | €4k | €3k | €1k | €730 | - |
| Net result for the period | 9904 | €9k | €8k | €3k | €10k | €8k |
| Result to be appropriated | 9905 | €9k | €8k | €3k | €10k | €8k |
| NACE primary | Research and development on biotechnology(72101) |
| Legal form | Private limited company(610) |
| Incorporation | 18-04-2011 |
| Status | Active |
| Postal code | 7911 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 57055B0169/00G000 | Wallonia | 968 m² | 1 · 276 m² | - |
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
11-01-2024 Transaction in capital or shares
Technical details
{
"events": [
{
"kind": "statutory_reserve_release",
"after_eur": null,
"delta_eur": null,
"before_eur": null,
"decrease_purpose": null,
"contribution_type": "reserves_incorporation",
"paid_up_delta_eur": null,
"n_shares_destroyed": null,
"not_yet_called_eur": null,
"merger_new_shares_n": null,
"merger_exchange_ratio": null,
"distribution_amount_eur": null,
"statutory_unavailable_equity_op": "suppress"
}
],
"notary": {
"name": "Marie-Sylvie DEWASME",
"firm_city": null,
"firm_name": "DEWASME, TUYTTENS, LENOBLE, Notaires associ\u00E9s",
"office_city": "Celles (Velaines)",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2024-01-11",
"filing_date": "2024-01-09",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "assembl\u00E9e_generale_extraordinaire",
"act_date": "2023-12-28",
"unanimous": true,
"under_authorized_capital": false,
"underlying_resolution_date": "2023-12-28"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0835.590.266",
"name_full": "TESPEBA",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
"is_foreign_registered": false
},
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"exp\u00E9dition de l\u0027acte",
"statuts coordonn\u00E9s conformes"
],
"shareholders_after": [],
"share_classes_after": []
}| Legal nameFR | TESPEBA |